# VSTM — Verastem Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** VSTM  
**Sources:** 29  
**Published:** 2026-10-21  
**Canonical:** https://app.k3vl4r.com/research/deep-research-vstm-verastem-inc-catalysts-narrative-risks-8518

---

## Verastem Oncology (VSTM) — Point-in-Time Research Summary (as of Oct 21, 2026)

**Company profile:** Verastem, Inc. (trading as Verastem Oncology; Nasdaq: VSTM; ISIN US92337C2035) is a Needham, Massachusetts-based development-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. Its portfolio includes an FDA-approved combination (avutometinib + defactinib, marketed as AVMAPKI FAKZYNJA CO-PACK) and an in-development oral KRAS G12D inhibitor, VS-7375. [[24]](https://finance.yahoo.com/quote/VSTM/), [[21]](https://www.verastem.com/our-medicines/), [[22]](https://www.verastem.com/), [[26]](https://www.verastem.com/our-science/pipeline/)

---

### Key recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-vstm-verastem-inc-catalysts-narrative-risks-8518 (free to sign up)._
